BioCentury
ARTICLE | Clinical News

HQK-1001: Completed Phase II enrollment

September 19, 2011 7:00 AM UTC

HemaQuest completed enrollment of 52 patients in an open-label, dose-escalation, international Phase II trial evaluating 30, 40 and 50 mg/kg oral HQK-1001 daily for 26 weeks. The compound has Orphan D...